Ultragenyx Pharmaceutical Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| UP0.F | QURE | DSGN | SNDX | PHAR | RGNX | |
|---|---|---|---|---|---|---|
| Market cap | 1.31B | 1.58B | 694.66M | 1.18B | 690.09M | 488.50M |
| P/E (TTM) | — | — | — | — | 75.0 | — |
| Forward P/E | -2.3 | -7.7 | -6.9 | -15.8 | 148.9 | -2.5 |
| Price/book | -5.0 | 4.9 | 3.4 | 78.4 | 2.6 | 5.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −56.24% | −64.80% | +88.99% | −13.88% | −32.87% | −45.38% |
| Today | +3.42% | +2.32% | +4.32% | +1.22% | +5.51% | +3.50% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All UP0.F news ›Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock
Posted by Defense World Staff on Oct 20th, 2026 Shares of Ultragenyx Pharmaceutical stock opened at $15.07 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $12.73 and a 12 month high of $39.89. The business’s 50-day moving…
Ultragenyx Pharmaceutical agrees to US$203M priority review voucher sale
Cash is payable at closing, subject to antitrust conditions; two announced voucher agreements total US$413 million. In the United States, a rare pediatric disease priority review voucher sale announced Wednesday carries a US$203 million…
Lobbying Update: $280,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed
$280,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. "Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues…
Ultragenyx Pharmaceutical (RARE) Sells $203M Priority Review Voucher Amid Gene Therapy Advances
On October 14, 2026, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced a $203 million agreement to sell a priority review voucher tied to the FDA approval of its gene therapy Fayuvi, targeting Sanfilippo syndrome type A in children.…
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on October 12th, the Representative disclosed that they had bought between…
Funds from operations of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
TradingView Funds from operations of Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical agrees to sell rare pediatric voucher for US$210M
The voucher came with Genglycos approval; payment awaits an antitrust waiting period and other closing conditions. A US$210 million payment is in prospect for Ultragenyx Pharmaceutical Inc. NASDAQRARE after it agreed on Wednesday to sell a…
Ultragenyx Pharmaceutical Inc. : Insider Transactions
Follow insider transactions on Ultragenyx Pharmaceutical Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Ultragenyx Pharmaceutical Inc. Latest insider transactions…
Ultragenyx Pharmaceutical Inc.: Relative Strength Chart - Stock Nasdaq
Compare Ultragenyx Pharmaceutical Inc. with the company of your choice via a Relative Strength chart. Real-time RARE price, Nasdaq stock exchange Relative Strength Chart Ultragenyx Pharmaceutical Inc. All financial news and data tailored…
Ultragenyx Pharmaceutical Inc.: News in other languages | RARE | US90400D1081
Ultragenyx Pharmaceutical Inc.: News, information and stories for Ultragenyx Pharmaceutical Inc. | Nasdaq: RARE | Nasdaq Other languages Ultragenyx Pharmaceutical Inc. All financial news and data tailored to specific country editions
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com11
-
mugglehead.com2
-
defenseworld.net1
-
gurufocus.com1
-
marketbeat.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.